Validation of FIB-6 score in assessment of liver fibrosis in chronic hepatitis B

Basit Öğe Kaydı
dc.authorid0000-0002-8909-2102en_US
dc.authorscopusid56035868800en_US
dc.authorwosidK-1194-2018en_US
dc.contributor.authorAlswat, Khalid
dc.contributor.authorSoliman, Riham
dc.contributor.authorMikhail, Nabiel N. H.
dc.contributor.authorÖrmeci, Necati
dc.contributor.authorDalekos, George N.
dc.contributor.authorDerbala, Moutaz F. M.
dc.contributor.authorAl-Busafi, Said Ahmed
dc.contributor.authorHamoudi, Waseem
dc.contributor.authorShiha, Gamal
dc.date.accessioned2024-03-18T08:12:01Z
dc.date.available2024-03-18T08:12:01Z
dc.date.issued2024en_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractBackground: We recently developed a simple novel index called fibrosis 6 (FIB‑6) using machine learning data analysis. We aimed to evaluate its performance in the diagnosis of liver fibrosis and cirrhosis in chronic hepatitis B (CHB). Methods: A retrospective observational analysis of data was obtained from seven countries(Egypt, Kingdom of Saudi Arabia (KSA), Turkey, Greece, Oman, Qatar, and Jordan) of CHB patients. The inclusion criteria were receiving an adequate liver biopsy and a complete biochemical and hematological data. The diagnostic performance analysis of the FIB‑6 index was conducted and compared with other non‑invasive scores. Results: A total of 603 patients were included for the analysis; the area under the receiver operating characteristic curve (AUROC) of FIB‑6 for the discrimination of patients with cirrhosis (F4), compensated advanced chronic liver disease (cACLD) (F3 and F4), and significant fibrosis (F2–F4) was 0.854, 0.812, and 0.745, respectively. The analysis using the optimal cut‑offs of FIB‑6 showed a sensitivity of 70.9%, specificity of 84.1%, positive predictive value (PPV) of 40.3%, and negative predictive value (NPV) of 95.0% for the diagnosis of cirrhosis. For the diagnosis of cACLD, the results were 71.5%, 69.3%, 40.8%, and 89.2%, respectively, while for the diagnosis of significant fibrosis, the results were 68.3%, 67.5%, 59.9%, and 75.0%, respectively. When compared to those of fibrosis 4 (FIB‑4) index, aspartate aminotransferase (AST)‑to‑platelet ratio index (APRI), and AST‑to‑alanine aminotransferase (ALT) ratio (AAR), the AUROC for the performance of FIB‑6 was higher than that of FIB‑4, APRI, and AAR in all fibrosis stages. FIB‑6 gave the highest sensitivity and NPV (89.1% and 92.4%) in ruling out cACLD and cirrhosis, as compared to FIB‑4 (63.8% and 83.0%), APRI (53.9% and 86.6%), and AAR (47.5% and 82.3%), respectively. Conclusions: The FIB‑6 index could be used in ruling out cACLD, fibrosis, and cirrhosis with good reliability.en_US
dc.identifier.citationAlswat, K., Soliman, R., Mikhail, N. N. H., Örmeci, N., Dalekos, G. N., Derbala, M. F. M., Al-Busafi, S. A., Hamoudi, W., & Shiha, G. (2024). Validation of FIB-6 score in assessment of liver fibrosis in chronic hepatitis B. Saudi Journal of Gastroenterology, 30(3), pp. 138-144. https://doi.org/10.4103/sjg.sjg_27_24en_US
dc.identifier.doi10.4103/sjg.sjg_27_24en_US
dc.identifier.endpage144en_US
dc.identifier.issue3en_US
dc.identifier.pmidPMID: 38482630en_US
dc.identifier.scopus2-s2.0-85193839974en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage138en_US
dc.identifier.urihttps://doi.org/10.4103/sjg.sjg_27_24
dc.identifier.urihttps://hdl.handle.net/20.500.13055/671
dc.identifier.volume30en_US
dc.identifier.wosWOS:001238537500007en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynak.otherSCI-E - Science Citation Index Expandeden_US
dc.institutionauthorÖrmeci, Necati
dc.language.isoenen_US
dc.publisherWolters Kluwer Healthen_US
dc.relation.ispartofSaudi Journal of Gastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCHBen_US
dc.subjectFIB‑6en_US
dc.subjectLiver Cirrhosisen_US
dc.subjectLiver Fibrosisen_US
dc.subjectNon‑Invasive Testsen_US
dc.titleValidation of FIB-6 score in assessment of liver fibrosis in chronic hepatitis Ben_US
dc.typeArticleen_US
dspace.entity.typePublication

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Validation of FIB-6 score in assessment of liver fibrosis in chronic hepatitis B.pdf
Boyut:
1.34 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu